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The mammalian Toll-like receptors (TLRs) expressed on dendritic 
cells (DCs), macrophages, and natural killer (NK) cells are so named 
because they have a high degree of sequence homology with the Dro-
sophila (fruit ﬂy) Toll gene, which is involved in embryogenesis and 
the innate response to fungal infections.1 Mammalian TLRs recognize 
highly conserved pathogen-associated molecular patterns common to 
bacteria, viruses, and parasites.2 Each type of TLR has a unique expres-
sion pattern and helps to direct an innate immune response that is ap-
propriate to the type of pathogen recognized, usually through secretion 
of large quantities of proinﬂammatory cytokines that help to limit the 
spread of infection. 
Toll-like receptor 9 (TLR9) is an intracellular receptor expressed by 
plasmacytoid DCs and B cells that detects unmethylated CpG se-
quences common to bacterial and viral DNA.3 In preclinical studies, 
short synthetic CpG oligodeoxynucleotides (ODNs) were shown to 
mimic viral or bacterial DNA sequences and activate TLR9.4,5 These 
TLR9 agonists have since been shown to induce activation of DCs and 
enhance cell surface expression of costimulatory molecules such as 
B7, which are required for full activation of T cells. In addition, TLR9 
agonists initiate a range of secondary effects including secretion of 
cytokines/chemokines, activation of NK cells, and proliferation of cyto-
toxic T lymphocytes that can target and lyse tumor cells, and thus may 
enhance the antitumor immune response.
In murine tumor models, TLR9 agonists have demonstrated single-
agent antitumor activity and have shown additive antitumor effects 
when combined with chemotherapy and radiotherapy. For example, in a 
murine cervical cancer model, mice were given subcutaneous injec-
tions of 1 × 106 C3 tumor cells and 9 daily doses of either 150 μg CpG 
ODNs or PBS.4 Mice treated with the TLR9 agonist had signiﬁcant re-
ductions in tumor size (P < .05) and signiﬁcantly improved survival (P 
< .001) compared with controls.4 Similarly, in a murine sarcoma model, 
tumor growth delay with single-dose radiation therapy was dramati-
cally enhanced by the addition of a TLR agonist (~2.6-fold).6 Systemic 
administration of a TLR9 agonist in combination with topotecan has 
also been shown to signiﬁcantly increase survival (41% survival with 
combination therapy versus 0% for controls; (P = .09) in a murine 
rhabdomyosarcoma model.7 Treatment with CpG ODNs and paclitaxel 
has also been shown to signiﬁcantly enhance survival (P < .0001) in a 
murine Lewis lung carcinoma model.8 Chemotherapy may enhance the 
activity of TLR9 agonists by killing tumor cells or disrupting the tumor 
stroma, thus making tumor-associated antigens more accessible to the 
immune system. In addition, several chemotherapy agents have been 
shown to enhance immune activation. For example, administration of 
taxanes enhances T-cell blastogenesis and the cytotoxic activity of NK 
cells, whereas cyclophosphamide reduces both the number and activity 
of regulatory T cells that can suppress the immune response to tumor 
antigens.9,10
Based on preclinical and early clinical studies indicating that the 
combination of a TLR9 agonist with chemotherapy has potential for 
the treatment of non-small cell lung cancer (NSCLC), a randomized, 
controlled phase II trial was conducted in chemotherapy-naive patients 
with stage IIIb/IV NSCLC. Patients were randomized 2:1 to receive 
either 4 to 6 cycles of taxane/platinum chemotherapy on Day 1 plus 
0.20 mg/kg PF 3512676 subcutaneously on Days 8 and 15 of each 
3-week cycle (n = 75) or chemotherapy alone (n = 37). The investiga-
tor-assessed objective response rate was 37% in the combination arm 
and 19% in the chemotherapy-alone arm (P = .048). Retrospective, 
independent radiological review of responses in 65 patients with avail-
able scans indicated a similar improvement in response rate (19% with 
combination therapy and 11% with chemotherapy alone). Furthermore, 
there was a trend toward improvement in median survival (12.2 months 
in the combination arm and 6.8 months in the chemotherapy-alone arm) 
and in 1-year survival rates (50% in the combination arm and 33% for 
the chemotherapy-alone arm).
The combination of PF-3512676 plus chemotherapy was generally well 
tolerated. The most common treatment-related side effects associated 
with PF-3512676 were mild to moderate injection-site reactions (eg, 
induration, pain, erythema, inﬂammation, or swelling) and ﬂu-like 
symptoms (eg, fatigue, myalgia, arthralgia, headache, rigor, fatigue, or 
musculoskeletal pain). Although there were increases in grade 3/4 neu-
tropenia, anemia, and thrombocytopenia in the PF-3512676 arm, there 
was no evidence of clinically important sequelae. This study suggests 
that the addition of PF-3512676 to standard doublet chemotherapy may 
provide signiﬁcant clinical beneﬁt without signiﬁcant added toxicity. 
Based on the results observed in this trial, 2 conﬁrmatory randomized, 
multicenter phase III trials are being conducted to determine the efﬁ-
cacy of PF-3512676 in combination with platinum-based chemotherapy 
(paclitaxel/carboplatin or gemcitabine/cisplatin) in chemotherapy-naive 
patients with stage IIIB/IV NSCLC. Exploratory phase II trials are also 
investigating the combination of PF-3512676 plus paclitaxel/carbopla-
tin/bevacizumab, erlotinib, or pemetrexed in patients with advanced 
NSCLC.
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